Safety and Efficacy of GENOSS® DCB With a Shellac Plus Vitamin E Excipient in Patients With De Novo Lesion

NCT07158307 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2025-09-05

No results posted yet for this study

Summary

The GENOSS PCB-De Novo study aims to evaluate the long-term efficacy and safety of a paclitaxel-coated balloon catheter containing shellac and vitamin E excipients (Genoss® DCB) in patients with De novo small coronary artery disease.

Conditions

  • Coronary Artery Disease(CAD)

Sponsors & Collaborators

  • Genoss Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-27
Primary Completion
2030-06-27
Completion
2031-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07158307 on ClinicalTrials.gov